GEROPHARM is an international producer of biotechnology products specializing in neurology, endocrinology, ophthalmology, gynecology, and urology. Its’ portfolio includes 35 original medicines and generics. GEROPHARM tops the Russian insulin market and is among the top 10 insulin manufacturers in the world. The Company runs all production stages at its own facilities in Russia by GxP standards. In 2023 GEROPHARM registered Semavic®, Russia's first Ozempic® analog, and in 2025 presented Mounjaro analog – Sejaro®. Medicinal products of the Company are represented in 14 countries.